People with immune thrombocytopenia (ITP) are at high risk of developing blood clots that block circulation, according to an analysis that combined results of…
News
Heavy menstrual bleeding (HMB) affects 93% of women with von Willebrand disease (VWD) at some point in life, according to a Swedish study that…
Pregnant women with thrombotic thrombocytopenic purpura (TTP) in the U.S. are nearly 20 times more likely to experience an adverse maternal outcome, according to…
An arm of the European Medicines Agency (EMA) is recommending that Wayrilz (rilzabrutinib) be approved to treat adults with immune thrombocytopenia (ITP) who…
Researchers created an experimental treatment for von Willebrand disease (VWD) type 1 that aims to stabilize the protein whose defect causes the disease, increasing…
Switching from treatment with fresh frozen plasma (FFP) to Adzynma (ADAMTS13, recombinant-krhn) can help people with congenital thrombotic thrombocytopenic purpura (TTP) avoid hospital stays,…
Older children with immune thrombocytopenia (ITP) who had had an infection tended to achieve sufficient levels of platelets — the cell fragments lost in…
Star Therapeutics has raised $125 million to support the development of VGA039, a treatment for von Willebrand disease (VWD) and other bleeding disorders…
COVID-19 may trigger or worsen refractory, or difficult-to-treat, thrombotic thrombocytopenic purpura (TTP) during the first months of pregnancy, requiring early diagnosis and aggressive treatment…
Patients with immune thrombocytopenia (ITP) who test positive for antinuclear antibodies (ANA), which mistakenly target the nucleus of cells, are at higher risk of…
